Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBIT Margin (2022 - 2025)

Axsome Therapeutics' EBIT Margin history spans 4 years, with the latest figure at 13.75% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 4739.0% year-over-year to 13.75%; the TTM value through Dec 2025 reached 26.12%, up 4662.0%, while the annual FY2025 figure was 26.12%, 4662.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 13.75% at Axsome Therapeutics, up from 26.97% in the prior quarter.
  • Across five years, EBIT Margin topped out at 6.74% in Q1 2023 and bottomed at 444.23% in Q2 2022.
  • The 4-year median for EBIT Margin is 75.34% (2024), against an average of 106.66%.
  • The largest annual shift saw EBIT Margin skyrocketed 30492bps in 2023 before it plummeted -8296bps in 2024.
  • A 4-year view of EBIT Margin shows it stood at 245.85% in 2022, then skyrocketed by 44bps to 137.39% in 2023, then surged by 55bps to 61.14% in 2024, then soared by 78bps to 13.75% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's EBIT Margin are 13.75% (Q4 2025), 26.97% (Q3 2025), and 24.47% (Q2 2025).